This pilot randomized Phase II trial (10 subjects per arm) will compare immune reconstitution
following transplantation of an autologous mobilized graft product to reconstitution
following transplantation of a mobilized graft product followed by an autologous lymphocyte
infusion collected prior to G-CSF mobilization. All subjects will receive tetanus vaccines
pre and post-transplant. The primary end point will be tetanus vaccine immune responses
1. To compare the cellular and humoral vaccine response post-transplant between the two
arms by performing Elisa, and T-cell enzyme-linked immunospot (ELISPOT) assays
2. To determine the feasibility and safety of this approach
1. To compare post-transplant recovery of innate and adaptive immune cells (CD8, CD4, CD19,
NK, γδ T-cells), in addition to T-cell phenotype markers between the two arms.
2. To compare post-transplant recovery of T-regs and MDSCs between the two arms.
3. To compare progression free survival (PFS) at 2 years post-transplant
1. Age ≥ 19 years to 70 years old at time of study entry (consent)
2. Diagnosis of Multiple Myeloma as per updated International Myeloma Working Group
(IMWG) criteria .
3. Must have measurable disease defined as: for secretory MM, serum monoclonal protein
≥1.0 g/dL, urine monoclonal protein ≥200 mg/24 hrs, and involved free light chain ≥ 10
mg/dL; or in case of non-secretory MM, bone marrow plasma cell percentage ≥30%.
4. Must have standard risk myeloma (see exclusion criterion 4).
5. Must have received bortezomib, lenalidomide and dexamethasone (VRd) as a form of
induction therapy pre-AHSCT (use of cyclophosphamide, bortezomib and dexamethasone may
be allowed for up to 2 weekly doses before initiation of VRd induction, if necessary
clinically for cytoreduction)
6. Able to understand and sign a consent form.
7. Creatinine clearance equal or > 60 ml/min (calculated)
8. Ejection fraction equal or > 50% before admission for transplant as per institutional
standards. Patients with coronary heart disease (recent myocardial infarctions,
angina, cardiac stent, or bypass surgery in the last 6 months or arrhythmia) need to
be cleared by cardiology as per institutional BMT standards.
9. Serum bilirubin, ALT, AST less than 3 X upper limit of normal
10. FVC, FEV1 or DLCO >50% predicted before admission for transplant as per institutional
standards. Patients on home oxygen are not allowed on the protocol.
11. No more than 6 months of pre-transplant MM chemotherapy is allowed (from the date of
the start of the induction therapy).
12. KPS ≥ 70%or ECOG 0-2.
13. Must be eligible to receive Melphalan dose of 200mg/m2
14. A female of child-bearing potential, must have two negative urine pregnancy test
results within 10 to 14 days prior to starting the first dose of vaccine
pre-transplant as a way of ensuring safe transplant planning.
1. Participation in another clinical study with an investigational product during the
last 28 days.
2. Prior stem cell transplant (either autologous or allogeneic)
3. Creatinine clearance < 60 ml/min (calculated)
4. High risk MM defined as those with the following disease, fluorescence in situ
hybridization and/or cytogenetic features: del17p, del1p with 1q gain, t(4;14),
t(14;16), t(14;20), >1 cytogenetic abnormality on karyotype, hypodiploid, plasma cell
leukemia (primary or secondary), or subjects who failed to achieve ≥PR to induction
therapy (i.e. VRd) and required salvage induction prior to AHSCT.
5. Documented central nervous system or extramedullary disease.
6. Significant organ dysfunction deemed to carry inappropriate risk for AHSCT.
7. Intention or plans for cyclophosphamide mobilization.
8. Known allergic reactions after previous tetanus diphtheria vaccination or had a
condition of Guillain Barre Syndrome (GBS)
9. Known active hepatitis B, C or HIV infections on initial assessment.
10. Enrollment on any other transplant related protocols.